BioCentury
ARTICLE | Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

June 26, 2018 6:52 PM UTC

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings targets. The parties expect the deal to close in July or early August.

Exosome's ExoDx Prostate(IntelliScore) is a urine-based test that detects three RNAs in exosomes and is used to predict whether men have high-risk prostate cancer prior to biopsy...